JBPHF (Jacobio Pharmaceuticals Group Co) 3-Year RORE % : -31.93% (As of Dec. 2025)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.42
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co 3-Year RORE %?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 3-Year RORE % is -31.93 as of Dec. 2025. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.42. The stock has 6 warning signs investors should review. Among 1,293 Biotechnology companies, Jacobio Pharmaceuticals Group Co ranks worse than 70.92% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Jacobio Pharmaceuticals Group Co's 3-Year RORE % for the quarter that ended in Dec. 2025 was -31.93%.

The industry rank for Jacobio Pharmaceuticals Group Co's 3-Year RORE % or its related term are showing as below:

JBPHF's 3-Year RORE % is ranked worse than
70.92% of 1293 companies
in the Biotechnology industry
Industry Median: -11.55 vs JBPHF: -31.93

Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Jacobio Pharmaceuticals Group Co 3-Year RORE % Related Terms


Jacobio Pharmaceuticals Group Co 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co 3-Year RORE % Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial -3.91 -51.88 1.01 -26.99 -31.93

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 1.99 -26.99 -46.31 -31.93

JBPHF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobio Pharmaceuticals Group Co 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's 3-Year RORE % falls into.


JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co 3-Year RORE % Calculation

Jacobio Pharmaceuticals Group Co's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.027--0.065 )/( -0.119-0 )
=0.038/-0.119
=-31.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -31.93 mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a 3-Year RORE % of -31.93 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #917 out of 1293 companies in the Biotechnology industry, placing it in the top 70.9%.
Is Jacobio Pharmaceuticals Group Co's 3-Year RORE % too high?
Jacobio Pharmaceuticals Group Co's current 3-Year RORE % is -31.93. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #917 out of 1293 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #917 out of 1293 companies for 3-Year RORE %. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current 3-Year RORE % is -31.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current 3-Year RORE % of -31.93. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current 3-Year RORE % is -31.93. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current 3-Year RORE % is -31.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.

Key valuation signals for JBPHF:

  • 3-Year RORE %: -31.93
  • GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.42
GF Value